ORIGINAL RESEARCH article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1589212
This article is part of the Research TopicEnhancing Prostate Cancer Diagnosis: Biomarkers and Imaging for Improved Patient OutcomesView all 11 articles
Diagnostic Value of [18F]PSMA-1007PET/CT based on PRIMARY Score Combined with mpMRI in Clinically Significant Prostate Cancer
Provisionally accepted
- Ningxia Medical University, Yinchuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction:ThisstudyaimedtoassessthediagnosticefficacyofthePRIMARYscore,basedon 20 the18F-labeledprostate-specificmembraneantigen(PSMA-1007)positronemissiontomography 21 (PET)/computedtomography(CT)withmultiparametricmagneticresonanceimaging(mpMRI)PI22 RADS,indetectingclinicallysignificantprostatecancer(csPCa).MaterialsandMethods: Inthis 23 retrospectivecohortstudy, 137patientswithsuspectedprostatecancer(PCa)underwent [18F]PSMA24 1007PET/CTandmpMRIbeforetransrectalultrasound(TRUS)-guidedneedlebiopsywas 25 performed.PatientswerecategorizedintocsPCaandnon-csPCagroupsbasedonhistopathological 26 findings.Thediagnosticperformanceoftotalprostate-specificantigen(TPSA),maximum 27 standardizeduptakevalue(SUVmax),thestandardizedProstateImagingReportingandDataSystem 28 (PI-RADSv2.1)ofmpMRI,andthePRIMARYscorewasevaluatedusingreceiveroperating 29 characteristic(ROC)curves.Theareaunderthecurve(AUC),sensitivity,andspecificitywere 30 calculated.FactorswithaP-value<0.05fromtheunivariateanalysiswereincludedinabinary 31 logisticregressionmodeltodevelopapredictivemodel.DifferencesintheAUCsforTPSA, 32 SUVmax,PI-RADSv2.1,thePRIMARYscore,andthecombinedmodelwerecomparedusing33 MedCalcsoftware.StatisticalsignificancewassetatP<0.05.Results:Amongthe137patients 34 evaluated,67.2%(92)wereincsPCaand32.8%(45)inthenon-csPCagroup(15withlow-grade 35 PCa[GS3+3]and30withbenignprostatichyperplasiaoracuteorchronicprostatitis).TPSA, 36 SUVmax,PI-RADSv2.1,andthePRIMARYscoresignificantlydifferedbetweenthetwogroups 37 (P<0.013).TheAUCsforTPSA,SUVmax,PI-RADSv2.1,andPRIMARYscorewere0.699,0.898, 38 0.878,and0.910,respectively,withcorrespondingdiagnosticsensitivitiesof53.3%,87.0%,90.2%, 39 and83.7%,andspecificitiesof23.0%,65.1%,42.6%,and58.5%,respectively.ThepredictiveROC 40 curveanalysisofthemodelrevealedanAUCof0.968,with91.3%sensitivity,and84.6%specificity. 41 MedCalcanalysisshowedthattheAUCofthemodelwassuperiorcomparedwiththatofSUVmax, 42 PI-RADSv2.1Score,andthePRIMARYscore.Thedifferencewasstatisticallysignificant(Z=2.273, 43 3.485,2.761;P=0.023,0.000,0.005).Conclusions:The5-gradePRIMARYscore,derivedfrom 44 [18F]PSMA-1007PET/CTinconjunctionwiththePI-RADSv2.1score,offersenhanced 45 discriminationofcsPCa
Keywords: [ 18 F]F-PSMA-1007, positron emission tomography/computed tomography, Multiparametric magnetic resonance imaging, prostate cancer, Molecular probe
Received: 07 Mar 2025; Accepted: 03 Jun 2025.
Copyright: © 2025 Ma, Hao, Chen, Pan, Li and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
YanMei Li, Ningxia Medical University, Yinchuan, China
Qian Zhao, Ningxia Medical University, Yinchuan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.